Pharsight

1. Desonate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6387383	LEO PHARMA AS	Topical low-viscosity gel composition	Aug, 2020 (3 years ago)

Market Authorisation Date: 20 October, 2006

Treatment: Desonate gel is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older

Dosage: GEL;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	01 Dec, 2010	1	11 May, 2020	03 Aug, 2020	Deferred

Strength	Dosage	Availability
0.05% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	GEL;TOPICAL	Discontinued

Application	Filing Date	Opposition Party	Legal Status

EP05775966A	2014-05-14	Henkel AG & Co. KGaA	Patent maintained as amended
EP05775966A	2014-05-14	Generics [UK] Limited	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6730288	ALMIRALL	Mousse composition	Sep, 2019 (4 years ago)
US7029659	ALMIRALL	Mousse composition	Sep, 2019 (4 years ago)
US9492384	ALMIRALL	Microemulsion and sub-micron emulsion process and compositions	Aug, 2025 (1 year, 4 months from now)
US8962000	ALMIRALL	Microemulsion and sub-micron emulsion process and compositions	Aug, 2025 (1 year, 4 months from now)
US8460641	ALMIRALL	Microemulsion process and composition	Aug, 2027 (3 years from now)

Market Authorisation Date: 19 September, 2006

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM;TOPICAL